Are JAK Inhibitors Safe for Dermatological Use? A Comprehensive Review of Clinical Trials and Monitoring Strategies.
Oral JAK inhibitors demonstrated low rates of venous thromboembolism, major adverse cardiovascular events, and malignancy in dermatology clinical trials, comparable to placebo. Most patients experiencing serious adverse events had pre-existing risk factors for those specific events.
Read More